Department of Ophthalmology, Faculty of Medicine, Süleyman Demirel University Hospital, 32260, Çünür, Isparta, Turkey.
Konya Eye Private Hospital, Isparta, Turkey.
Int Ophthalmol. 2022 May;42(5):1545-1552. doi: 10.1007/s10792-021-02145-w. Epub 2022 Jan 7.
To evaluate the efficiency of low-dose intravitreal ranibizumab therapy in the treatment of aggressive retinopathy of prematurity (A-ROP).
A total of 124 eyes of 62 patients who underwent intravitreal ranibizumab after an A-ROP diagnosis between January 2015 and January 2021 were evaluated retrospectively. After receiving family-approved informed consent, low-dose intravitreal ranibizumab was administered, and regular follow-ups were performed.
Patients included in the study had a mean birth week of 26.6 (23-33 weeks), a mean birth weight of 905 (450-1970) grams, and an average injection postnatal time of 9.1 (4-19) weeks. The mean follow-up period was 63 (24-250) weeks. In all eyes, ROP regressed in the first week after injection, and no asymmetrical response was observed in the eyes of any baby. A total of 58 eyes recovered with a single dose of intravitreal injection therapy, and peripheral retinal vascularization was completed. A second injection was required in 38 eyes. Rescue treatment was applied in addition to intravitreal ranibizumab treatment in 22 eyes of 11 babies. None of the patients had any ocular or systemic side effects.
Low-dose intravitreal ranibizumab injection with close follow-up and appropriate timing is an effective treatment modality in A-ROP. Even among patients undergoing rescue laser treatment, the treatment can be completed with a wide visual field.
评估小剂量玻璃体内雷珠单抗治疗早产儿侵袭性视网膜病变（A-ROP）的疗效。
回顾性分析 2015 年 1 月至 2021 年 1 月期间诊断为 A-ROP 并接受玻璃体内雷珠单抗治疗的 62 例患者的 124 只眼。在获得家属同意后，给予小剂量玻璃体内雷珠单抗治疗，并进行定期随访。
研究纳入的患者平均出生孕周为 26.6（23-33 周），平均出生体重为 905（450-1970）g，平均生后注射时间为 9.1（4-19）周。平均随访时间为 63（24-250）周。所有患眼在注射后第 1 周ROP 均消退，且未观察到任何婴儿的眼出现不对称反应。58 只眼单次玻璃体内注射治疗后痊愈，周边视网膜血管化完成。38 只眼需要再次注射。11 例患儿的 22 只眼除玻璃体内雷珠单抗治疗外，还进行了挽救性激光治疗。所有患者均无眼部或全身不良反应。
小剂量玻璃体内雷珠单抗注射结合密切随访和适时治疗是 A-ROP 的有效治疗方法。即使在需要进行挽救性激光治疗的患者中，也可以通过广泛的视场完成治疗。
